Pieper Steven — SEC insider filings
SEC reporting owner CIK 1875714. 19 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2021-07-29 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 53,000 shares, $104,518 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 5 filings — 65,000 shares, $566,386 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
- Largest priced transaction: sale of 27,600 shares @ $8.52 ($235,276) in Xeris Biopharma Holdings, Inc., filed 2026-07-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | See Remarks | 17 | 2 legs · 53,000 sh · $104,518 | 6 legs · 65,000 sh · $566,386 | 38 |
| XERIS PHARMACEUTICALS INC (XERS) | Chief Financial Officer | 2 | — | — | 8 |
Insider filings — Pieper Steven
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 5,000 @ $10.23 | EDGAR |
| 2026-10-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 5,000 @ $9.41 | EDGAR |
| 2026-09-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 5,000 @ $8.50 | EDGAR |
| 2026-08-12 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 5,000 @ $8.50 | EDGAR |
| 2026-07-07 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 17,400 @ $8.50 · Sale (S): 27,600 @ $8.52 | EDGAR |
| 2026-03-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Option exercise (M): 27,891 @ $4.09 · Option exercise (M): 14,036 @ $5.93 · Option exercise (M): 27,891 (derivative) @ $0 · Option exercise (M): 14,036 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 154,986 @ $0 · Tax withholding (F): 111,765 @ $7.36 · Tax withholding (F): 66,450 @ $7.36 · Tax withholding (F): 27,319 @ $7.36 · Grant/award (A): 207,207 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 110,750 @ $3.56 · Tax withholding (F): 66,450 @ $3.56 · Grant/award (A): 185,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 32,059 @ $3.61 | EDGAR |
| 2024-11-26 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Option exercise (M): 19,483 @ $1.55 · Option exercise (M): 16,843 (derivative) @ $0 · Option exercise (M): 2,640 (derivative) @ $0 | EDGAR |
| 2024-08-09 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Tax withholding (F): 3,460 @ $2.11 · Tax withholding (F): 750 @ $2.11 · Tax withholding (F): 9,767 @ $1.43 · Tax withholding (F): 23,067 @ $1.12 · Tax withholding (F): 3,590 @ $1.26 · Tax withholding (F): 778 @ $1.24 · +5 more | EDGAR |
| 2024-01-31 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 450,000 @ $0 | EDGAR |
| 2023-11-21 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Purchase (P): 28,000 @ $1.95 | EDGAR |
| 2023-02-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 750,000 @ $0 | EDGAR |
| 2022-01-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2021-11-12 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Purchase (P): 25,000 @ $2.00 | EDGAR |
| 2021-10-05 | 4 | XERIS PHARMACEUTICALS INC (XERS) | Disposition to issuer (D): 23,775 · Disposition to issuer (D): 134,333 · Disposition to issuer (D): 16,843 (derivative) · Disposition to issuer (D): 2,640 (derivative) · Disposition to issuer (D): 14,036 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +1 more | EDGAR |
| 2021-10-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 23,775 · Grant/award (A): 134,333 · Grant/award (A): 16,843 (derivative) · Grant/award (A): 2,640 (derivative) · Grant/award (A): 14,036 (derivative) · Grant/award (A): 12,500 (derivative) · +1 more | EDGAR |
| 2021-07-29 | 4 | XERIS PHARMACEUTICALS INC (XERS) | Grant/award (A): 100,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-04-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1875714 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs